A new diagnostic test developed by researchers at the University of Reading, University of Southampton, and Hampshire Hospitals NHS Foundation Trust promises to dramatically reduce the time to effective treatment for urinary tract infections (UTIs), delivering results within approximately 5.85 hours – a significant improvement over the current two-to-three-day laboratory turnaround. This advancement aims to combat rising antibiotic resistance and improve patient outcomes by ensuring targeted therapy is initiated promptly.
UTIs represent a substantial burden on global healthcare systems. The delay in identifying the causative bacterial agent and its antibiotic susceptibility profile often leads to empirical treatment – the use of broad-spectrum antibiotics before definitive results are available. While necessary in many cases, this practice contributes to the escalating crisis of antimicrobial resistance (AMR), where bacteria evolve to withstand the effects of antibiotics. This new test directly addresses this challenge by providing rapid, actionable information to clinicians, potentially minimizing unnecessary broad-spectrum antibiotic use.
In Plain English: The Clinical Takeaway
- Faster Answers: This test can tell doctors which antibiotic will work against your UTI in about 6 hours, instead of waiting 2-3 days.
- Reduced Antibiotic Resistance: By using the right antibiotic sooner, One can help prevent bacteria from becoming resistant to these life-saving drugs.
- Lower Risk of Complications: Getting the correct treatment quickly reduces the chance of a UTI becoming a more serious infection, like sepsis.
The Science Behind Rapid UTI Diagnosis
The conventional method for UTI diagnosis involves urine culture, a process requiring overnight incubation to allow bacterial colonies to grow. This allows for identification of the pathogen and subsequent antibiotic susceptibility testing. The new method, however, bypasses this lengthy culturing step. It utilizes a cartridge containing small tubes preloaded with different antibiotics. When a urine sample is introduced, the system employs optical imaging to monitor bacterial growth within each tube. Inhibition of bacterial growth indicates antibiotic effectiveness, while continued growth suggests resistance. This direct-from-urine approach significantly accelerates the diagnostic process.
The research, published in the Journal of Antimicrobial Chemotherapy, demonstrated a high degree of accuracy. Across seven commonly used first-line antibiotics, the new test aligned with standard laboratory methods in 96.95% of cases, evaluated across 352 urine samples. Crucially, a secondary analysis involving 90 duplicate samples, some preserved with boric acid, showed 98.75% agreement, confirming that standard urine preservation techniques do not interfere with test accuracy. What we have is particularly important for widespread implementation within existing clinical workflows.
Geographical Impact and Regulatory Pathways
The potential impact of this technology is particularly significant for healthcare systems grappling with high rates of antibiotic resistance and overburdened laboratories. In the United Kingdom, the National Health Service (NHS) alone analyzes approximately 65 million urine samples annually, and UTIs contribute to over 800,000 hospital admissions over the past five years. The rapid diagnostic test, developed by Astratus Limited – a spin-out company from the University of Reading established in November 2024 – is poised to alleviate some of this pressure.
The pathway to widespread clinical adoption will involve regulatory approval. In the UK, this will likely involve demonstrating compliance with Medicines and Healthcare products Regulatory Agency (MHRA) standards. In the United States, Astratus Limited would demand to pursue clearance from the Food and Drug Administration (FDA), potentially through the De Novo classification process for novel diagnostic tests. The FDA has been increasingly focused on promoting rapid diagnostics to combat AMR, as outlined in their National Action Plan for Combating Antibiotic-Resistant Bacteria.
“Rapid diagnostics are essential to our efforts to combat antibiotic resistance. They allow us to prescribe the right antibiotic, to the right patient, at the right time, reducing the selective pressure that drives resistance.”
– Dr. Jesse Goodman, former Chief Scientist at the FDA, speaking at the 2025 IDSA conference.
Funding and Potential Biases
The research underpinning this new test was funded by the National Institute for Health and Care Research (NIHR) in the UK. It’s important to acknowledge that Astratus Limited, the company commercializing the technology, has a vested interest in its successful implementation. While the NIHR funding provides a degree of independence, potential biases related to commercialization should be considered. The company’s CEO, Dr. Oliver Hancox, has publicly emphasized the clinical benefits of the test, highlighting the potential to reduce sepsis rates and improve patient care.
Data Summary: Test Performance
| Metric | Value |
|---|---|
| Total Samples Evaluated | 352 |
| Agreement with Standard Lab Methods (Overall) | 96.95% |
| Agreement with Standard Lab Methods (Preserved Samples) | 98.75% |
| Average Test Time | 5.85 hours |
| Number of Antibiotics Tested Simultaneously | 7 |
The Broader Context of AMR and UTI Management
Escherichia coli (E. Coli) remains the most common causative agent of UTIs, accounting for approximately 75-85% of uncomplicated infections. However, increasing rates of extended-spectrum beta-lactamase (ESBL)-producing E. Coli are a growing concern globally. ESBLs are enzymes that confer resistance to many commonly used beta-lactam antibiotics, including penicillins and cephalosporins. The rapid diagnostic test’s ability to quickly identify antibiotic susceptibility patterns is particularly valuable in managing infections caused by ESBL-producing organisms. The World Health Organization (WHO) has identified ESBL-producing Enterobacterales as a critical priority pathogen, necessitating urgent action to preserve antibiotic effectiveness. WHO Priority Pathogens
the rise of multi-drug resistant organisms (MDROs) in UTIs is linked to factors such as frequent antibiotic use, hospitalization, and international travel. Effective surveillance and infection control measures are crucial to mitigate the spread of MDROs. The rapid diagnostic test can contribute to these efforts by enabling targeted antibiotic therapy and reducing the selective pressure for resistance development.
Contraindications & When to Consult a Doctor
This test is designed for use by healthcare professionals in a laboratory setting. It’s not a self-diagnosis tool. Individuals experiencing symptoms of a UTI – including frequent urination, burning sensation during urination, cloudy urine, and pelvic pain – should consult a doctor for proper evaluation and treatment. The test is not suitable for individuals with complex UTIs, such as those associated with kidney infections (pyelonephritis) or underlying anatomical abnormalities. In cases of severe symptoms, such as fever, chills, flank pain, or nausea, immediate medical attention is required, as these may indicate a more serious infection like sepsis.
The development of this rapid diagnostic test represents a significant step forward in the fight against antibiotic resistance and the improvement of UTI management. While regulatory hurdles and widespread implementation challenges remain, the potential benefits for patients and healthcare systems are substantial. Continued research and innovation in rapid diagnostics are essential to address the evolving threat of AMR and ensure the availability of effective treatments for infectious diseases.
References
- Hancox, O. Et al. (2026). Rapid direct-from-urine antibiotic susceptibility testing for urinary tract infection. Journal of Antimicrobial Chemotherapy.
- World Health Organization. (2024). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report.
- National Institute for Health and Care Research (NIHR). (2025). Funding Opportunities. https://www.nihr.ac.uk/
- Centers for Disease Control and Prevention. (2023). Antibiotic Resistance Threats in the United States. https://www.cdc.gov/drugresistance/threats.html
- FDA. (2024). Combating Antibiotic Resistance. https://www.fda.gov/public-health/antibiotic-resistance
